n(6)-cyclohexyladenosine has been researched along with Myocardial-Ischemia* in 10 studies
1 review(s) available for n(6)-cyclohexyladenosine and Myocardial-Ischemia
Article | Year |
---|---|
Ischemic preconditioning--do we need more (pharmacological) experiments?
Topics: Adenosine; Animals; Blood Flow Velocity; Bradykinin; Coronary Vessels; Humans; Ischemic Preconditioning, Myocardial; Myocardial Ischemia; Norepinephrine; Purinergic P1 Receptor Agonists | 1997 |
9 other study(ies) available for n(6)-cyclohexyladenosine and Myocardial-Ischemia
Article | Year |
---|---|
Role of glucose metabolism in the recovery of postischemic LV mechanical function: effects of insulin and other metabolic modulators.
The role of proton (H+) production from glucose metabolism in the recovery of myocardial function during postischemic reperfusion and its alteration by insulin and other metabolic modulators were examined. Rat hearts were perfused in vitro with Krebs-Henseleit solution containing palmitate (1.2 mmol/l) and glucose (11 mmol/l) under nonischemic conditions or during reperfusion following no-flow ischemia. Perfusate contained normal insulin (n-Ins, 50 mU/l), zero insulin (0-Ins), or supplemental insulin (s-Ins, 1,000 mU/l) or other metabolic modulators [dichloroacetate (DCA) at 3 mmol/l, oxfenicine at 1 mmol/l, and N6-cyclohexyladenosine (CHA) at 0.5 micromol/l]. Relative to n-Ins, 0-Ins depressed rates of glycolysis and glucose oxidation in nonischemic hearts and impaired recovery of postischemic function. Relative to n-Ins, s-Ins did not affect aerobic glucose metabolism and did not improve recovery when present during reperfusion. When present during ischemia and reperfusion, s-Ins impaired recovery. Combinations of metabolic modulators with s-Ins stimulated glucose oxidation approximately 2.5-fold in nonischemic hearts and reduced H+ production. DCA and CHA, in combination with s-Ins, improved recovery of function, but addition of oxfenicine to this combination provided no further benefit. Although DCA and CHA were each partially protective in hearts perfused with n-Ins, optimal protection was achieved with DCA + CHA; recovery of function was inversely proportional to H+ production during reperfusion. Although supplemental insulin is not beneficial, elimination of H+ production from glucose metabolism by simultaneous inhibition of glycolysis and stimulation of glucose oxidation optimizes recovery of postischemic mechanical function. Topics: Adenosine; Animals; Dichloroacetic Acid; Energy Metabolism; Enzyme Inhibitors; Glucose; Glycine; Glycolysis; Hydrogen-Ion Concentration; In Vitro Techniques; Insulin; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Palmitic Acid; Perfusion; Rats; Rats, Sprague-Dawley; Time Factors; Ventricular Dysfunction, Left | 2008 |
Alteration of glycogen and glucose metabolism in ischaemic and post-ischaemic working rat hearts by adenosine A1 receptor stimulation.
1. Cardioprotection by adenosine A1 receptor activation limits infarct size and improves post-ischaemic mechanical function. The mechanisms responsible are unclear but may involve alterations in myocardial glucose metabolism. 2. Since glycogen is an important source of glucose during ischaemia, we examined the effects of N6-cyclohexyladenosine (CHA), an A1 receptor agonist, on glycogen and glucose metabolism during ischaemia as well as reperfusion. 3. Isolated working rat hearts were perfused with Krebs-Henseleit solution containing dual-labelled 5-3H and 14C glucose and palmitate as energy substrates. Rates of glycolysis and glucose oxidation were measured directly from the production of 3H2O and 14CO2. Glycogen turnover was measured from the rate of change of [5-3H and 14C]glucosyl units in total myocardial glycogen. 4. Following low-flow (0.5 ml min-1) ischaemia (60 min) and reperfusion (30 min), left ventricular minute work (LV work) recovered to 22% of pre-ischaemic values. CHA (0.5 microM) improved the recovery of LV work 2 fold. 5. CHA altered glycogen turnover in post-ischaemic hearts by stimulating glycogen synthesis while having no effects on glycogen degradation. CHA also partially inhibited glycolysis. These changes accelerated the recovery of glycogen in CHA-treated hearts and reduced proton production. 6. During ischaemia, CHA had no measurable effect on glycogen turnover or glucose metabolism. Glycogen phosphorylase activity, which was elevated after ischaemia, was inhibited by CHA, possibly in response to CHA-induced inhibition of AMP-activated protein kinase activity. 7. These results indicate that CHA-induced cardioprotection is associated with alterations of glycogen turnover during reperfusion as well as improved metabolic coupling of glycolysis to glucose oxidation. Topics: Adenosine; Adenylate Kinase; Aerobiosis; Animals; Glucose; Glycogen; Glycogen Synthase; Glycolysis; Heart Ventricles; In Vitro Techniques; Kinetics; Male; Myocardial Ischemia; Myocardial Reperfusion; Myocardium; Palmitic Acid; Phosphates; Phosphorylases; Protons; Purinergic P1 Receptor Agonists; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P1; Ventricular Function | 1999 |
K(ATP)-channel activation: effects on myocardial recovery from ischaemia and role in the cardioprotective response to adenosine A1-receptor stimulation.
1. Optimization of myocardial energy substrate metabolism improves the recovery of mechanical function of the post-ischaemic heart. This study investigated the role of K(ATP)-channels in the regulation of the metabolic and mechanical function of the aerobic and post-ischaemic heart by measuring the effects of the selective K(ATP)-channel activator, cromakalim, and the effects of the K(ATP)-channel antagonist, glibenclamide, in rat fatty acid perfused, working hearts in vitro. The role of K(ATP) channels in the cardioprotective actions of the adenosine A1-receptor agonist, N6-cyclohexyladenosine (CHA) was also investigated. 2. Myocardial glucose metabolism, mechanical function and efficiency were measured simultaneously in hearts perfused with modified Krebs-Henseleit solution containing 2.5 mM Ca2+, 11 mM glucose, 1.2 mM palmitate and 100 mu l(-1) insulin, and paced at 300 beats min(-1). Rates of glycolysis and glucose oxidation were measured from the quantitative production of 3H20 and 14CO2, respectively, from [5-3H/ U-14C]-glucose. 3. In hearts perfused under aerobic conditions, cromakalim (10 microM), CHA (0.5 microM) or glibenclamide (30 microM) had no effect on mechanical function. Cromakalim did not affect glycolysis or glucose oxidation, whereas glibenclamide significantly increased rates of glycolysis and proton production. CHA significantly reduced rates of glycolysis and proton production but had no effect on glucose oxidation. Glibenclamide did not alter CHA-induced inhibition of glycolysis and proton production. 4. In hearts reperfused for 30 min following 30 min of ischaemia, left ventricular minute work (LV work) recovered to 24% of aerobic baseline values. Cromakalim (10 microM), administered 5 min before ischaemia, had no significant effect on mechanical recovery or glucose metabolism. CHA (0.5 microM) significantly increased the recovery of LV work to 67% of aerobic baseline values and also significantly inhibited rates of glycolysis and proton production. Glibenclamide (30 microM) significantly depressed the recovery of mechanical function to < 1% of aerobic baseline values and stimulated glycolysis and proton production. 5. Despite the deleterious actions of glibenclamide per se in post-ischaemic hearts, the beneficial effects of CHA (0.5 microM) on the recovery of mechanical function and proton production were not affected by glibenclamide. 6. The data indicate that the cardioprotective mechanism of adenosine A1-receptor stimulation d Topics: Adenosine; Adenosine Triphosphate; Animals; Blood Pressure; Coronary Circulation; Glucose; In Vitro Techniques; Male; Myocardial Ischemia; Myocardial Reperfusion; Potassium Channels; Purinergic P1 Receptor Agonists; Rats; Rats, Sprague-Dawley; Vascular Resistance; Ventricular Function, Left | 1998 |
A novel cardioprotective function of adenosine A1 and A3 receptors during prolonged simulated ischemia.
The possible cardioprotective roles of adenosine A1 and A3 receptors were investigated in a cardiac myocyte model of injury. The adenosine A3 receptor is a novel cardiac receptor capable of mediating potentially important cardioprotective functions. Prolonged hypoxia with glucose deprivation was used to simulate ischemia and to induce injury in cardiac ventricular myocytes cultured from chick embryos 14 days in ovo. When present during the prolonged hypoxia, the adenosine A3 agonists N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide (IB-MECA) and 2-chloro-N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide (CI-IB-MECA) caused a dose-dependent reduction in the extent of hypoxia-induced injury as manifested by a decrease in the amount of creatine kinase released and the percentage of myocytes killed. The adenosine A1 agonists 2-chloro-N6-cyclopentyladenosine (CCPA), N6-cyclohexyladenosine, and adenosine amine congener were also able to cause a decrease in the extent of myocyte injury. The A1 receptor-selective antagonist 8-cyclopentyl-1,3-dipropylxanthine blocked the cardioprotective effect of the A1 but not of the A3 agonists. Conversely, the selective A3 antagonists MRS-1191 and MRS-1097 blocked the protection induced by CI-IB-MECA but had minimal effect on that caused by CCPA. Thus the cardioprotective effects of A1 and A3 agonists were mediated by their respective receptors. This study defines a novel cardioprotective function of the cardiac A3 receptor and provides conclusive evidence that activation of both A1 and A3 receptors during hypoxia can attenuate myocyte injury. Topics: Adenosine; Animals; Cardiotonic Agents; Cell Hypoxia; Cells, Cultured; Chick Embryo; Dihydropyridines; Heart; Heart Ventricles; Myocardial Ischemia; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Receptor, Adenosine A3; Receptors, Purinergic P1; Xanthines | 1997 |
Inhibition of glycolysis and enhanced mechanical function of working rat hearts as a result of adenosine A1 receptor stimulation during reperfusion following ischaemia.
1. This study examined effects of adenosine and selective adenosine A1 and A2 receptor agonists on glucose metabolism in rat isolated working hearts perfused under aerobic conditions and during reperfusion after 35 min of global no-flow ischaemia. 2. Hearts were perfused with a modified Krebs-Henseleit buffer containing 1.25 mM Ca2+, 11 mM glucose, 1.2 mM palmitate and insulin (100 muu ml-1), and paced at 280 beats min-1. Rates of glycolysis and glucose oxidation were measured from the quantitative production of 3H2O and 14CO2, respectively, from [5-3H/U-14C]-glucose. 3. Under aerobic conditions, adenosine (100 microM) and the adenosine A1 receptor agonist, N6-cyclohexyladenosine (CHA, 0.05 microM), inhibited glycolysis but had no effect on either glucose oxidation or mechanical function (as assessed by heart rate systolic pressure product). The improved coupling of glycolysis to glucose oxidation reduced the calculated rate of proton production from glucose metabolism. The adenosine A1 receptor antagonist, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX 0.3 microM) did not alter glycolysis or glucose oxidation per se but completely antagonized the adenosine- and CHA-induced inhibition of glycolysis and proton production. 4. During aerobic reperfusion following ischaemia, CHA (0.05 microM) again inhibited glycolysis and proton production from glucose metabolism and had no effect on glucose oxidation. CHA also significantly enhanced the recovery of mechanical function. In contrast, the selective adenosine A2a receptor agonist, CGS-21680 (1.0 microM), exerted no metabolic or mechanical effects. Similar profiles of action were seen if these agonists were present during ischaemia and throughout reperfusion or when they were present only during reperfusion. 5. DPCPX (0.3 microM), added at reperfusion, antagonized the CHA-induced improvement in mechanical function. It also significantly depressed the recovery of mechanical function per se during reperfusion. Both the metabolic and mechanical effects of adenosine (100 microM) were antagonized by the nonselective A1/A2 antagonist, 8-sulphophenyltheophylline (100 microM). 6. These data demonstrate that inhibition of glycolysis and improved recovery of mechanical function during reperfusion of rat isolated hearts are mediated by an adenosine A1 receptor mechanism. Improved coupling of glycolysis and glucose oxidation during reperfusion may contribute to the enhanced recovery of mechanical function by decreasing proton pr Topics: Adenosine; Animals; Energy Metabolism; Glycolysis; Heart; Male; Myocardial Ischemia; Myocardial Reperfusion; Purinergic P1 Receptor Agonists; Rats; Rats, Sprague-Dawley; Xanthines | 1996 |
Ischemic preconditioning: bioenergetic and metabolic changes and the role of endogenous adenosine.
The role of adenosine in ischemic preconditioning in different species remains controversial. Ischemic preconditioning was examined in perfused rat and rabbit hearts. In rat and rabbit hearts subjected to 30 min global normothermic ischemia followed by 30 min of reperfusion, left ventricular developed pressure (LVDP) recovered to 36 +/- 8% and 44 +/- 7% of preischemia, respectively. Pre-treatment with transient (6 min) global ischemia improved recovery of LVDP (75 +/- 7% and 82 +/- 9% pre-ischemia, respectively), and improved recovery of coronary flow and end-diastolic pressure. Effects of preconditioning were unrelated to cytosolic [ATP], but were associated with reduced ischemic acidosis, and improved post-ischemic recovery of [Mg2+], [P(i)] and delta GATP. In addition to ischemia, transient episodes of hypoxia (5% O2), norepinephrine stimulation (0.1 microM) or metabolic inhibition (5 mM cyanide minus glycolytic substrate) all improved recovery from prolonged ischemia. Microdialysis revealed that 6 min of ischemic preconditioning increased dialysate [adenosine] from 0.25 to 6.81 +/- 0.87 microM in rat hearts, and from 0.33 to 1.98 +/- 0.41 microM in rabbit hearts. Extracellular [adenosine] was also enhanced during the transient periods of hypoxia, norepinephrine stimulation and metabolic inhibition shown to be protective. Pre-treatment with 0.5 microM Nb-cyclohexyladenosine mimicked preconditioning, and 50 microM 8-(rho-sulfophenyl) theophylline attenuated ischemic preconditioning in rat and rabbit hearts. 8-(rho-sulfophenyl) theophylline also abolished effects of preconditioning on ischemic acidosis, and post-ischemic [Mg2+], [P(i)] and delta GATP. The data demonstrate that (i) preconditioning is triggered by transient periods of energy imbalance: (ii) endogenous adenosine is of primary importance in mediating the cardioprotection following a single transient ischemic stimulus in rat and rabbit hearts; and (iii) post-receptor mechanisms of this adenosine-mediated preconditioning appear to involve reduced ischemic acidosis and enhanced recovery of [P(i)], [Mg2+] and delta GATP. Topics: Adenosine; Adenosine Diphosphate; Adenosine Triphosphate; Animals; Coronary Circulation; Energy Metabolism; Heart; Hydrogen-Ion Concentration; In Vitro Techniques; Ischemic Preconditioning, Myocardial; Magnesium; Magnetic Resonance Spectroscopy; Male; Microdialysis; Myocardial Ischemia; Myocardial Reperfusion; Myocardium; Oxygen Consumption; Phosphates; Phosphocreatine; Phosphorus; Rabbits; Rats; Rats, Sprague-Dawley; Species Specificity; Time Factors; Ventricular Function, Left | 1996 |
Antecedent ischemia reverses effects of adenosine on glycolysis and mechanical function of working hearts.
This study compared the effects of adenosine (Ado) on the coupling of glycolysis and glucose oxidation and on mechanical function in normal hearts and in hearts subjected to transient ischemia. Isolated working rat hearts were perfused with Krebs containing 1.2 mM palmitate and 100 microU/ml insulin. After 15 min of aerobic perfusion, hearts underwent either two cycles of 10 min of ischemia and 5 min of reperfusion (stressed) or 30 min of aerobic perfusion (control). After 45 min, hearts underwent either aerobic perfusion for 35 min (series A) or 30 min of ischemia and 30 min of reperfusion (series B). In series A, left ventricular minute work (LV work) was similar in control and stressed hearts and was not affected by Ado (500 microM) or N6-cyclohexyladenosine (CHA 0.5 microM). Ado reduced glycolysis by 49% in control hearts but increased glycolysis by 74% in stressed hearts. CHA inhibited glycolysis in both groups by 50 and 62%, respectively. In series B, LV work during reperfusion recovered to a similar extent in untreated control and stressed hearts. In control hearts, Ado reduced glycolysis by 50% while enhancing LV work to 81% of preischemic values. In stressed hearts, Ado increased glycolysis by 34% and depressed LV work to 9%, whereas CHA inhibited glycolysis by 53% and LV work to 91%. These data indicate that coupling of glycolysis to glucose oxidation is a key determinant of mechanical function of the postischemic myocardium. They also show that the metabolic and protective effects of Ado depend on the status of the heart before sustained ischemia. Topics: Adenosine; Animals; Cardiovascular Agents; Glycogen; Glycolysis; Myocardial Ischemia; Myocardial Reperfusion; Rats; Rats, Sprague-Dawley; Stress, Physiological; Ventricular Function, Left | 1996 |
Pertussis toxin blocks adenosine A1 receptor mediated protection of the ischemic rat heart.
Adenosine and acetylcholine exert negative chronotropic and anti-adrenergic effects on nonischemic myocardium presumably via receptor coupling to the same or similar inhibitory guanine nucleotide binding protein (Gi). To determine whether the cardioprotective effect of adenosine is mediated via adenosine A1 receptor coupling to Gi proteins, isolated rat hearts, perfused at constant pressure and constant heart rate, were subjected to 30 min global normothermic (37 degrees C) ischemia and 45 min reperfusion. Untreated control hearts recovered 52 +/- 2% of preischemic left ventricular developed pressure (LVDP). Hearts treated for 10 minutes prior to ischemia with adenosine (100 microM) and the adenosine A1 receptor agonist cyclohexyladenosine (CHA, 0.25 microM) recovered 67 +/- 4% and 70 +/- 4%, respectively. Hearts treated with the non-specific muscarinic cholinergic agonist carbamylcholine (1 microM) exhibited similar enhanced postischemic recovery (70 +/- 3%). Pretreatment of rats with pertussis toxin (25 micrograms/kg i.p., 48 h prior to isolation) significantly reduced the negative chronotropic effects of adenosine and CHA. Pertussis toxin pretreatment also blocked the beneficial effects of adenosine (57 +/- 4% recovery) and CHA (49 +/- 4% recovery) on postischemic function. These results support the hypothesis that the salutary effect of adenosine on the ischemic myocardium is mediated via adenosine A1 receptor coupling to a pertussis toxin sensitive G protein, presumably Gi. Topics: Adenosine; Animals; Carbachol; GTP-Binding Proteins; Heart; Heart Rate; Hemodynamics; Male; Myocardial Ischemia; Myocardium; Pertussis Toxin; Rats; Rats, Wistar; Receptors, Purinergic P1; Time Factors; Virulence Factors, Bordetella | 1993 |
Adenosine improves recovery of postischemic myocardial function via an adenosine A1 receptor mechanism.
The effects of adenosine in the nonischemic heart have been shown to be mediated via its binding to extracellular adenosine A1 and A2 receptors located predominantly on myocytes and endothelial cells, respectively. We tested the hypothesis that the beneficial effect of adenosine on postischemic myocardial function is mediated via an adenosine A1 receptor mechanism. Isolated rat hearts perfused at constant pressure (85 cmH2O) were subjected to 30 min of global no-flow ischemia (37 degrees C) and 45 min of reperfusion. Hearts treated with adenosine (100 microM) and the adenosine A1 receptor agonist N6-cyclohexyladenosine (CHA; 0.25 microM) recovered 72 +/- 4 and 70 +/- 4% of preischemic left ventricular developed pressures (LVDP), respectively, after 45 min of reperfusion compared with untreated hearts (54 +/- 3% of preischemic LVDP). Adenosine and CHA hearts exhibited greater myocardial ATP contents than control hearts after 10 min of ischemia, but there were no differences in tissue ATP levels after 30 min of ischemia. In contrast, hearts treated with the adenosine A2 receptor agonist phenylaminoadenosine (0.25 microM) failed to demonstrate improved postischemic function (52 +/- 5%). The addition of the A1-selective antagonist 8-cyclopentyl-1,3-dipropylxanthine blocked the cardioprotective effect of adenosine (57 +/- 4%). These results suggest that adenosine enhances postischemic myocardial function via an A1 receptor mechanism. Topics: Adenine Nucleotides; Adenosine; Animals; Hemodynamics; In Vitro Techniques; Male; Myocardial Ischemia; Myocardial Reperfusion; Myocardium; Rats; Rats, Wistar; Receptors, Purinergic; Xanthines | 1992 |